مجلس الضمان الصحي
Council of Health Insurance

Myelofibrosis

CHI Formulary Treatment algorithm

Treatment algorithm- October 2023

Supporting treatment algorithms for the clinical management of myelofibrosis

Figures 1 to 4 outline a comprehensive treatment algorithm on **the management of Myelofibrosis** aimed at addressing the different lines of treatment after thorough review of medical and economic evidence by CHI committees.

For further evidence, please refer to CHI **Myelofibrosis** full report. You can stay updated on the upcoming changes to our formulary by visiting our website at https://chi.gov.sa/AboutCCHI/CCHIprograms/Pages/IDF.aspx

Our treatment algorithm offers a robust framework for enhancing patient care and optimizing treatment outcomes across a range of treatment options, holding great promise for improving healthcare delivery.



1

Figure 1: Treatment algorithm of myelofibrosis in low-risk

[1] NCCN Clinical Practice Guidelines in Oncology (Myeloproliferative Neoplasms, Version 2.2023)



[2]

Figure 2: Treatment algorithm for the management of Myelofibrosis in High-risk

[2] NCCN Clinical Practice Guidelines in Oncology (Myeloproliferative Neoplasms, Version 2.2023)



Figure 3: Treatment algorithm for the management of Myelofibrosis[3]

[3] NCCN Clinical Practice Guidelines in Oncology (Myeloproliferative Neoplasms, Version 2.2023)



4

Figure 4: Treatment algorithm for the management of accelerated blast phase/MF

[4] NCCN Clinical Practice Guidelines in Oncology (Myeloproliferative Neoplasms, Version 2.2023)